The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension

Journal of Hypertension

Volumn 23, Issue 10, 2005, Pages 1777-1781

  Mason, James M ^a   Dickinson, Heather O ^b   Nicolson, Donald J ^c   Campbell, Fiona ^b   Ford, Gary A ^b   Williams, Bryan ^d  

^a DURHAM UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Beta blockers; Drug therapy; Hypertension; Iatrogenic harm; New onset diabetes; Thiazide type diuretics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 29244448292     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000177537.91527.09     Document Type: Review

References (34)

1. Cranston W, Juel-Jensen B, Semmence A, Handfield Jones R, Forbes J, Mutch L. Effects of oral diuretics on raised arterial pressure. Lancet 1963; 2:966-969.
2. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976; 1:564-566.
3. Medical Research Council. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of the Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2:543-549.
4. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982; 2:1293-1295.
5. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-2110.
6. Schneider M, Lerch M, Papiri M, Buechel P, Boehlen L, Shaw S, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996; 14:669-677.
7. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298:1152-1157.
8. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868-873.
9. Harper R, Ennis CN, Sheridan B, Atkinson AB, Johnston GD, Bell PM. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309:226-230.
10. Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473.
11. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities (ARIC) Study. N Engl J Med 2000; 342:905-912.
12. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22:1453-1458.
13. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22:1845-1847.
14. Messerli FH, Grossman E, Leonetti G. Diuretics and new onset diabetes: is it a problem? J Hypertens 2005; 23:668-669.
15. Verdecchia P, Borgioni C, Angeli F, Reboldi G, Gattobigio R, Fillipucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
16. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 327:290-291.
17. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19:1139-1147.
18. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
19. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
20. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al., for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
22. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
23. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
24. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
25. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
26. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-2427.
27. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
28. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 2004; 27:247-255.
29. Sever PS, Dahlof B, for the Anglo-Scandinavian Cardiac Outcomes Trial. Morbidity-mortality outcomes in the blood pressure-lowering arm of the trial (ASCOT-BPLA). Oral Presentation (410-5) to the American College of Cardiology: annual scientific meetings. 8 March 2005. Orlando, FL, USA and www.heart.org. Accessed 15 March 2005.
30. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-1574.
31. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
32. North of England Hypertension Guideline Development Group. Essential hypertension: managing adult patients in primary care. Centre for Health Services Research, report no. 111. Newcastle: University of Newcastle; 2004.
33. National Institute for Clinical Excellence. Management of hypertension in adults in primary care. Clinical Guideline 18. August 2004. Available at: http://www.nice.org.uk/pdf/CG018NICEguideline.pdf. Accessed: 10 May 2005.
34. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al., for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.